InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,192.56
(
0.23%
)
US TECH 100
17,610.80
(
0.00%
)
Dow Jones
38,904.81
(
0.14%
)
Brent Oil
82.90
(
-0.69%
)
Bitcoin
63,657.99
(
0.79%
)
Post# of 136
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

chucktarman51

Send PM Follow Ignore
Followers 0
Posts 1
Boards Moderated 0
Alias Born 12/03/2014

chucktarman51

Re: None

Wednesday, 12/03/2014 10:56:07 AM

Wednesday, December 03, 2014 10:56:07 AM

Post# of 136
BOPH Severely undervalued vs its peers

Bayer just completed its purchase of Chinese TCM-manufacturer Dihon Pharmaceutical for just under $600 million. Bohai (BOPH) produces revenue similar to Dihon with one-quarter of the workforce. (Dihon is private and its bottom line numbers are not available.) This puts the value of BOPH, on a comparative revenue basis, at close to $30/share.

http://www.press.bayer.com/baynews/baynews.nsf/id/Bayer-completes-acquisition-of-Dihon-Pharmaceutical-Group-Co-Ltd-in-China
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up